Literature DB >> 22148555

Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.

Roger B Clark1, Diana K Hunt, Minsheng He, Catherine Achorn, Chi-Li Chen, Yonghong Deng, Corey Fyfe, Trudy H Grossman, Philip C Hogan, William J O'Brien, Louis Plamondon, Magnus Rönn, Joyce A Sutcliffe, Zhijian Zhu, Xiao-Yi Xiao.   

Abstract

Utilizing a fully synthetic route to tetracycline analogues, the C-9 side-chain of the fluorocyclines was optimized for both antibacterial activity and oral efficacy. Compounds were identified that overcome both efflux (tet(K), tet(A)) and ribosomal protection (tet(M)) tetracycline-resistance mechanisms and are active against Gram-positive and Gram-negative organisms. A murine systemic infection model was used as an oral efficacy screen to rapidly identify compounds with oral bioavailability. Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens. One compound demonstrated oral efficacy in rodent lung infection models that was comparable to marketed antibacterial agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22148555     DOI: 10.1021/jm201467r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 2.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 3.  Natural Products as Platforms To Overcome Antibiotic Resistance.

Authors:  Sean E Rossiter; Madison H Fletcher; William M Wuest
Journal:  Chem Rev       Date:  2017-09-27       Impact factor: 60.622

Review 4.  Tetracycline Antibiotics and Resistance.

Authors:  Trudy H Grossman
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

Review 5.  Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Authors:  George G Zhanel; Doris Cheung; Heather Adam; Sheryl Zelenitsky; Alyssa Golden; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Andrew Walkty; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 6.  Biosynthesis of Oxytetracycline by Streptomyces rimosus:
Past, Present and Future Directions in the Development
of Tetracycline Antibiotics.

Authors:  Hrvoje Petković; Tadeja Lukežič; Jagoda Šušković
Journal:  Food Technol Biotechnol       Date:  2017-03       Impact factor: 3.918

7.  Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.

Authors:  Trudy H Grossman; Agata L Starosta; Corey Fyfe; William O'Brien; David M Rothstein; Aleksandra Mikolajka; Daniel N Wilson; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

8.  In vitro activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia species.

Authors:  Michael Cynamon; Jeff Jureller; Balaji Desai; Krithika Ramachandran; Mary Sklaney; Trudy H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

9.  Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.

Authors:  J A Sutcliffe; W O'Brien; C Fyfe; T H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 10.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.